Biochemical Profiling of Arsenic Trioxide-Induced Impaired Carbohydrate Metabolism and its Therapeutic Intervention via Modulation of Metabolic Pathways

We aimed to investigate the impact of arsenic trioxide (ATO) in impairing carbohydrate metabolism and therapeutic potential of resveratrol (RSV) to treat ATO-induced metabolic disorder. Twenty Wistar rats were used for this study; one group was normal control (NC), second group was exposed to ATO only while the other two groups received metformin (MF) and RSV separately along with ATO. We measured serum levels of glycemic index biomarkers and carbohydrate metabolizing enzymes. Simultaneously, we also measured arsenic concentration in liver using HG-AAS technique. ATO exposed rats showed a significant elevation in serum glucose, reduction in serum insulin, rise in insulin resistance and alteration of carbohydrate metabolizing biomarkers when compared with unexposed rats. Arsenic concentration was found to be significantly high in liver tissues of ATO exposed rats. Contrarily, RSV was found to be effective in regulating normal glycemic level, insulin tolerance, and metabolic biomarkers. Hence, it was found that ATO exposure is correlated with onset of impaired metabolism and RSV can be used as therapeutic intervention for arsenic-induced impaired metabolism.